MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

From Medicineworld.org: Slow Release Octreotide Increases survival in Carcinoid Syndrome

Cancer Main Cancer News What is cancer?  

Slow Release Octreotide Increases survival in Carcinoid Syndrome

Data presented by Lowell Anthony MD, of the Louisiana State University health Science Center, New Orleans, at the 2005 Gastrointestinal Cancer Symposium (abstract 101) shows that use of long-acting release (LAR) octreotide (Sandostatin LAR depot) is associated with longer survival compared to used of conventional three-times daily formulation, in patients with malignant carcinoid syndrome.

The median survival in 143 patients who received the Sandostatin LAR Depot was 229 months. This is statistically significant when compared to cohort controls treated with conventional short acting octreotide, who had a median survival of 143 months (p<0.0001, hazard ratio 0.34).

We were surprised at the magnitude of the survival difference, but with hindsight, it seems reasonable. " Dr. Anthony said "The original dose must be administered subcutaneously three times per day. Many patients have problems with this schedule, and we know form clinical experience that many only take two doses per day. Since each dose covers only 6 hours, patients who are receiving drug for only about 12 hours per day. The LAR dose provides much better coverage and essentially takes the compliance issue out of the equation."

The study was conducted between 1995 and 2004 on 229 consecutive patients and the results were compared to 90 control patients who were treated with short acting octreotide between 1986 and 1994.

The study should be used with caution since this is not a randomized trial. Many variable that may have occurred between the study periods including but not limited to advancement of debulking surgery such as hepatic resection, radio-frequency ablation, and embolization were not taken in to account in evaluating the study. Dr. Anthony does not think these variables cannot account for such dramatic increase in survival in patients who received the LAR preparation.

Cancer terms:
Remission: Partial or complete disappearance of tumor and cancer symptoms. Partial remission refers to decrease in the size of a tumor with partial relief of symptoms, while complete remission refers to complete disappearance of tumor and symptoms. Example: Mr. B had a large tumor, with three chemotherapy treatments, he had a partial remission and with six treatments he had complete remission. See cancer terms for more cancer related terms.

Medicineworld.org: Slow Release Octreotide Increases survival in Carcinoid Syndrome

Cancer terms| History of cancer| Imaging techniques| Cancer Main| Bladder cancer news| Cervix cancer news| Colon cancer news| Esophageal cancer news| Gastric cancer news| Health news| Lung cancer news| Breast cancer news| Ovarian cancer news| Cancer news| Pancreatic cancer news| Prostate cancer news| Endometrial cancer news| General info| What is cancer?| Cancer causes| Is cancer hereditary?| Types of cancer| Cancer statistics| Breast cancer main| Breast cancer symptoms| Colon cancer main| Anal cancer| Bladder cancer main| Lung cancer general| Lung cancer main| Non small cell| Small cell| Ovarian cancer main| Treatment of ovarian cancer| Prostate cancer main| Updates in oncology|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.